Cambridge Cognition Holdings plc (LON:COG), which develops and markets digital solutions to assess brain health, has announced that it has won a new contract with a major pharmaceutical client to provide digital assessments of mood and cognition for a depression trial. The contract is worth over £700,000 with most of the revenue expected to be recognised in 2021.
Impairments in cognition can persist after recovery from a period of depression and this can contribute to difficulties in reaching a full recovery. So, in efforts to thoroughly assess treatment efficacy, Cambridge Cognition has been contracted to deploy remote assessments of mood and cognition over a 12-month period. The assessments will be delivered on patients’ mobile phones with their performance and wellbeing monitored by the pharmaceutical client.
The inclusion of remote and brief assessments during both the core and extension periods of the trial will provide the client with a better understanding of the relationships between mood, cognition and recovery. Cambridge Cognition is in a unique position to support the delivery of this trial with expertise in both gold-standard cognitive assessment and innovative digital health solutions for frequent, remote testing.
Matthew Stork, Chief Executive Officer of Cambridge Cognition Holdings, said:
“We are excited to be working with another pharmaceutical company that recognises the importance of frequent objective cognitive assessments in the development of treatments for central nervous system disorders. This new contract further validates the Company’s strategy as again we will be configuring existing digital health solutions rather than undertaking bespoke software development. It also further highlights the opportunity available to Cambridge Cognition to provide remote, patient-centred solutions in the CNS market.”
